ALKERMES | ALKS - Ebitda

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.93B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	Ebitda	更改		日
AbbVie	USD 3.69B		1.68B	2026-03
Acadia Pharmaceuticals	USD 20.31M		15.44M	2025-12
ALKERMES	USD 139.22M		58.96M	2026-06
Amgen	USD 5.14B		775M	2025-12
Biogen	USD 649.7M		76.5M	2026-03
BioMarin Pharmaceutical	USD 146.05M		170.22M	2026-03
Bristol-Myers Squibb	USD 4.24B		1.37B	2026-03
Coherus Biosciences	USD -43.33M		4.7M	2025-09
Eli Lilly	USD 12.14B		4.26B	2025-12
Gilead Sciences	USD 3.02B		1.01B	2025-12
Heron Therapeutics	USD -3.88M		5.63M	2024-09
Ionis Pharmaceuticals	USD -64.53M		135.49M	2026-03
J&J	USD 8.27B		1.08B	2026-03
Malin Corporation	EUR -1.1M		200K	2024-12
Merck	USD 6.3B		2.09B	2025-12
Minerva Neurosciences	USD -4.36M		1.71M	2024-09
Nektar Therapeutics	USD -38.9M		7.09M	2026-03
Neurocrine Biosciences	USD 193.3M		25.1M	2026-03
Otsuka Holdings	JPY 156.66B		56.89B	2026-03
Pfizer	USD 5.99B		5.23B	2026-03
Regeneron Pharmaceuticals	USD 1.66B		695.2M	2026-06
Vertex Pharmaceuticals	USD 1.19B		195.3M	2026-03